HBM HOLDINGS-B Announces First Patient Dosed in Phase II COPD Trial for Its Long-Acting TSLP Antibody

Stock News06-09 20:20

HBM HOLDINGS-B (ASX: 02142) has announced that its partner, Windward Bio AG, has dosed the first patients in the Phase II SIRIUS study evaluating HBM9378, also known as WIN378 or SKB378, for the treatment of chronic obstructive pulmonary disease (COPD).

The drug candidate is a fully human, ultra-long-acting, targeted thymic stromal lymphopoietin (TSLP) antibody. The SIRIUS trial is a global, randomized, double-blind, placebo-controlled, dose-ranging Phase II study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378 in patients with moderate-to-severe COPD.

HBM9378 is also being evaluated in Windward Bio's Phase II/III POLARIS study for asthma, with initial Phase II data expected in the second half of 2026. Windward Bio anticipates that the first Phase III asthma study for HBM9378 will commence in the fourth quarter of 2026.

The initiation of the SIRIUS COPD study expands the clinical development of HBM9378 into COPD as a second major respiratory disease. The board of HBM HOLDINGS-B believes that the start of this study marks continued clinical progress for HBM9378 and provides further evidence of the molecule's potential as a differentiated, ultra-long-acting targeted TSLP antibody for treating immune-mediated diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165433802?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165433802","market":"sg","top_or_hot":-1,"title":"HBM HOLDINGS-B Announces First Patient Dosed in Phase II COPD Trial for Its Long-Acting TSLP Antibody","media":"Stock News","content":"<p>HBM HOLDINGS-B (<b>ASX: 02142</b>) has announced that its partner, Windward Bio AG, has dosed the first patients in the Phase II SIRIUS study evaluating HBM9378, also known as WIN378 or SKB378, for the treatment of chronic obstructive pulmonary disease (COPD).<br><br>The drug candidate is a fully human, ultra-long-acting, targeted thymic stromal lymphopoietin (TSLP) antibody. The SIRIUS trial is a global, randomized, double-blind, placebo-controlled, dose-ranging Phase II study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378 in patients with moderate-to-severe COPD.<br><br>HBM9378 is also being evaluated in Windward Bio's Phase II/III POLARIS study for asthma, with initial Phase II data expected in the second half of 2026. Windward Bio anticipates that the first Phase III asthma study for HBM9378 will commence in the fourth quarter of 2026.<br><br>The initiation of the SIRIUS COPD study expands the clinical development of HBM9378 into COPD as a second major respiratory disease. The board of HBM HOLDINGS-B believes that the start of this study marks continued clinical progress for HBM9378 and provides further evidence of the molecule's potential as a differentiated, ultra-long-acting targeted TSLP antibody for treating immune-mediated diseases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM HOLDINGS-B Announces First Patient Dosed in Phase II COPD Trial for Its Long-Acting TSLP Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM HOLDINGS-B Announces First Patient Dosed in Phase II COPD Trial for Its Long-Acting TSLP Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-09 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM HOLDINGS-B (<b>ASX: 02142</b>) has announced that its partner, Windward Bio AG, has dosed the first patients in the Phase II SIRIUS study evaluating HBM9378, also known as WIN378 or SKB378, for the treatment of chronic obstructive pulmonary disease (COPD).<br><br>The drug candidate is a fully human, ultra-long-acting, targeted thymic stromal lymphopoietin (TSLP) antibody. The SIRIUS trial is a global, randomized, double-blind, placebo-controlled, dose-ranging Phase II study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378 in patients with moderate-to-severe COPD.<br><br>HBM9378 is also being evaluated in Windward Bio's Phase II/III POLARIS study for asthma, with initial Phase II data expected in the second half of 2026. Windward Bio anticipates that the first Phase III asthma study for HBM9378 will commence in the fourth quarter of 2026.<br><br>The initiation of the SIRIUS COPD study expands the clinical development of HBM9378 into COPD as a second major respiratory disease. The board of HBM HOLDINGS-B believes that the start of this study marks continued clinical progress for HBM9378 and provides further evidence of the molecule's potential as a differentiated, ultra-long-acting targeted TSLP antibody for treating immune-mediated diseases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1165433802","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165433802","pubTimestamp":1781007639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HBM HOLDINGS-B (ASX: 02142) has announced that its partner, Windward Bio AG, has dosed the first patients in the Phase II SIRIUS study evaluating HBM9378, also known as WIN378 or SKB378, for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B","BK1161":"生物科技","BK1583":"高瓴概念","BK1574":"生物医药B类股"},"translate_title":"HBM HOLDINGS-B宣布其长效TSLP抗体II期COPD试验中首例患者接受给药","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM HOLDINGS-B (ASX: 02142) has announced that its partner, Windward Bio AG, has dosed the first patients in the Phase II SIRIUS study evaluating HBM9378, also known as WIN378 or SKB378, for the treatment of chronic obstructive pulmonary disease (COPD).The drug candidate is a fully human, ultra-long-acting, targeted thymic stromal lymphopoietin (TSLP) antibody. The SIRIUS trial is a global, randomized, double-blind, placebo-controlled, dose-ranging Phase II study designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9378 in patients with moderate-to-severe COPD.HBM9378 is also being evaluated in Windward Bio's Phase II/III POLARIS study for asthma, with initial Phase II data expected in the second half of 2026. Windward Bio anticipates that the first Phase III asthma study for HBM9378 will commence in the fourth quarter of 2026.The initiation of the SIRIUS COPD study expands the clinical development of HBM9378 into COPD as a second major respiratory disease. The board of HBM HOLDINGS-B believes that the start of this study marks continued clinical progress for HBM9378 and provides further evidence of the molecule's potential as a differentiated, ultra-long-acting targeted TSLP antibody for treating immune-mediated diseases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165433802","isCrawlerRequest":true}